Action ANRO ALTO NEUROSCIENCE, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Alto Neuroscience, Inc.

Actions

ANRO

US02157Q1094

Marché Fermé - Nyse
Autres places de cotation
 22:00:02 27/06/2024 		Varia. 5j. Varia. 1 janv.
10,63 USD +6,73% Graphique intraday de Alto Neuroscience, Inc. -3,80% 0,00%
20/06 Alto Neuroscience, Inc. lance une étude de phase 2 sur ALTO-101, un nouvel inhibiteur de la PDE4, dans les troubles cognitifs associés à la schizophrénie CI
21/05 Alto Neuroscience, Inc. nomme Michael Hanley au poste de directeur des opérations CI

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Alto Neuroscience, Inc.(NYSE:ANRO) added to S&P Global BMI Index
Alto Neuroscience Initiates Phase 2 Study of ALTO-101, a Novel PDE4 Inhibitor, in Cognitive Impairment Associated with Schizophrenia
Alto Neuroscience, Inc. Initiates Phase 2 Study of ALTO-101, Novel PDE4 Inhibitor, in Cognitive Impairment Associated with Schizophrenia
Amit Etkin, M.D., Ph.D., Founder and CEO of Alto Neuroscience, Named an EY Entrepreneur of the Year 2024 Bay Area Award Winner
Amit Etkin, M.D., Ph.D., Founder and CEO of Alto Neuroscience, Named an EY Entrepreneur Of The Year® 2024 Bay Area Award Winner
Alto Neuroscience to Present at the Jefferies Global Healthcare Conference
Alto Neuroscience Appoints Michael Hanley as Chief Operating Officer
Alto Neuroscience, Inc. Appoints Michael Hanley as Chief Operating Officer
Alto Neuroscience, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Alto Neuroscience Reports First Quarter 2024 Financial Results and Recent Business Highlights
Alto Neuroscience Announces Data Presentations Highlighting Late-Stage Clinical Pipeline and Robust Platform at Upcoming Scientific Conferences
Alto Neuroscience Announces Positive Phase 1 Results for ALTO-101, a Novel PDE4 Inhibitor in Development for Schizophrenia
Alto Neuroscience, Inc. Announces Positive Phase 1 Results for ALTO-101, A Novel PDE4 Inhibitor in Development for Schizophrenia
Alto Neuroscience Starts Phase 2 Trial of ALTO-203 in Major Depressive Disorder Patients
Alto Neuroscience Announces Initiation of Phase 2 Study of ALTO-203 in Patients with Major Depressive Disorder
Alto Neuroscience, Inc. Announces Initiation of Phase 2 Study of Alto-203 in Patients with Major Depressive Disorder
Alto Neuroscience Reports Full Year 2023 Financial Results and Recent Business Highlights
Alto Neuroscience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Alto Neuroscience, Inc.(NYSE:ANRO) added to S&P TMI Index
Alto Neuroscience Appoints Maha Radhakrishnan, M.D., to Board of Directors
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action ANRO
  4. Actualités Alto Neuroscience, Inc.
  5. Autres langues